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SUMMARY 
One-hundred-and-fifteen patients diagnosed as anxiety neurotics randomly received in a double blind 
study 20 mg clobazam (Frisium) as a single nightly dose (37 patients) or 10 mg b.d. (38 patients) or diazepam 5 mg 
ti.d. (40 patients) for six weeks, followed by two weeks on placebo. Both the single and divided doses of clobazam 
were therapeutically equivalent to diazepam. After drug withdrawal, all three treatment groups continued to im-
prove. Patients on clobazam showed better motor performance than the diazepam series. Patients on clobazam di-
vided dose performed significantly better than those on diazepam. Minor side-effects occurred in all patients. From 
the results clobazam as a single dose of 20 mg has good anxiolysis without any hungover effect. 
The objective of this study was a com-
parison of anxiolytic efficacy of clobazam 
as either a single or equally divided 20mg 
daily dosage with that of 5 mg diazepam 
thrice daily. Earlier studies have suggested 
that clobazam may have a prolonged anxio-
lytic effect, and have drawn attention to 
the need to investigate the drug at doses 
lower than 30 pig/day (Doongaji et al 
1978). 
Material and Methods 
Of 115 patients available for analysis, 38 re-
ceived clobazam (Frisium) in two equally 
divided doses of 10 mg at morning and 10 
mg at night, 37 patients received a single 20 
n\g dose at night and 40 patients received 5 
mg of diazepam three times a day. Treat-
ment distribution was randomized and ad-
ministered by a double-dummy technique 
such that at each dosing patients always re-
ceived numerically two identical capsules. 
Identical placebo capsules were substituted 
for clobazam or diazepam whenever re-
quired. 
All patients scored at least 14 on the Ha-
milton Anxiety Rating Scale (1959) and at 
least 2 on the symptoms of General Somatic 
(muscular, sensory and anxious mood). 
Patients with clinical evidence of any 
pathology affecting absorption, metabolism 
or excretion were excluded from the study. 
Pregnancy or its possibility did not permit 
the entry of females to the study. For the 
first six weeks all patients received active 
treatment and for the next two weeks pla-
cebo therapy was given. This phase of pla-
cebo treatment was single-blind, the pa-
tients being unaware of the treatment they 
were receiving. 
Evaluation was done at weekly intervals 
on the HARS by an experienced research 
worker and on the Clinical Global Impres-
sion (CGI) Scale (Guy 1976) by the princi-
pal investigator. 
At the evaluation, motor coordination 
was tested on the pursuit rotor. After the fa-
. miliarization run, the average of three runs 
(each of 30 sec) was taken as the efficacy 
criterion. 
Result* 
Patient characteristics are presented in 
Table 1. The percentage reduction on the 
initial HARS scores for the three groups is 
shown in Table 2. Both the single and di-
vided doses of clobazam were comparable 
to diazepam in therapeutic efficacy at the 
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Table 1 
Demographic Characteristics of the 155 Pitienti 
Treatment 
Clobazam 
3
 
No. of 
Patient) 
38 
37 
Male 
28 
26 
Female 
(Yean) 
10 
11 
(35) 
Mean Age ± SE 
(kg) 
28.18 ± 0.99 
27.77 $ 0.97 
Mean Weight ± SE Mean Duration of Illness 
(months) 
55.45 ± 124 13.66 ± 1.44 
54.41 ± 11.11 14.39 ± 1.77 
(36) 
Diazepam 40 
(5 mg t.i.a) 
28  12  27.56 ±105  56 ±1 
(39) 
56.63 ± 1.54  13.60 ± 1.63 
Table 2 
Percentage Reduction in Initial HARS Scores 
Treatment 
Clabazam 
(10-10mg) 
Clobazam 
(20 mg) 
Diazepam 
(5 mg t.i.d.) 
Day 8 
2158 
23.41 
22.79 
Day 15 
3322 
32.77 
35.16 
Active Treatment 
Day 22 
47.57 
4838 
47.83 
Day 29 
56.10 
57.66 
54.91 
Day 36 
64.68 
66,72 
63.71 
Day 43 
68.85 
71.48 
69.77 
Placebo 
Day 50 
23.76 
2122 
21.08 
Day 57 
35.97 
3S.37 
32.96 
Percentage reduction in placebo period is with reference to Day 43. 
end of the six-week treatment period. Dur-
ing the next two weeks on placebo, further 
reduction in the anxiety scores were ob-
served in equal measure for all three treat-
ment groups. 
On the clusters of psychic and somatic 
anxiety, statistical comparison revealed that 
diazepam did not differ from either the 
single or the divided dosage schedule of 
clobazam. 
At the end of the six weeks' active drug 
treatment, five variables in each of the se-
ries of clobazam single dose and diazepam, 
responded with over 75% improvement 
(Table 3). In the clobazam divided dose 
group only two variables showed more 
than 75 % improvement. 
In the post treatment period on placebo, 
the percentage reduction for the psychic 
anxiety cluster was highest (39 %) in the 
Table3 
Hars Variables Showing at least 75 % improvement on Day 43 
Clobazam 
(10- tOmg) 
Clobazam 
(20 mg) 
Diazepam 
(5 mg ti.d.) 
Respiration 
Genito-urinary 
Depressed mood 
General somatic, sensory 
Respiration 
Gastrointestinal 
Genito-urinary 
Fears 
Depressed moqd 
General somatic, sensory 
Genito-urinary 
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single dose series compared with 35% in 
the divided dose series and 30% in the dia-
zepam scries. 
On the somatic anxiety cluster, during 
post-treatment placebo therapy, the divid-
ed dose group showed further percentage 
reduction of 36%. In the single dose group 
34% further reduction was seen and diaze-
pam treated patients responded with a fur-
ther improvement of 35%. 
On the CGI evaluation, the percentage of 
responders who showed at least marked im-
provement were analysed (Table 4). Patients 
on clobazam single dose responded better 
than the remainder two groups at the end of 
both treatments and the placebo periods. 
Table 4 
Percentage of patients showing at least marked 
improvements 
Figure 
Dav 
Clobazam Diazepam 
(20 mg) (10-10 mg) (5 mg tj.d.) 
8 
15 
22 
29 
36 
43 
50 
57 
2.7 
5.4 
17.2 
29.6 
50.0 
60.0 
70.8 
79.2 
2.7 
13.5 
15.6 
28.1 
38.7 
51.6 
61.3 
72.0 
10.3 
10.3 
17.1 
22.9 
48.6 
55.6 
68.6 
743 
No significant difference by the Chi square test. 
Motor Coordination 
All three groups of patients (Figure) 
showed significant improvement in motor 
performance as early as the end of the first 
week of treatment. Improvement conti-
nued till the end of the six weeks' drug 
treatment period and the trend was main-
tained even during the subsequent two 
weeks on placebo therapy. 
Both the clobazam single and divided 
dose series showed better motor perfor-
mance than the diazepam group through-
out the study. From Day 15 until Day 50, 
patients who received clobazam divided 
dosage performed significantly better than 
the diazepam group of patients. 
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Side effects: 
Minor side effects were present in all 
three treatment groups. Under Cloba-
zam conditions two patients complained 
of an itching sensation and one deve-
loped a rash on the arm and back. Two 
other complaints volunteered were abdo-
minal pain and apprehension from the 
clobazam divided dose and diazepam se-
ries. 
Pain in the limbs was reported by two 
patients one of whom had received clo-
bazam and the other diazepam. These re-
ported side-effects were transient. No 
treatments was administered and they re-
gressed spontaneously. 
Discussion 
This study was designed to investigate 
the anxiolytic activity of clobazam either as 
a 20 mg single or divided dose, compared to 
diazepam in a 5 mg thrice daily schedule. 
Clobazam has already been investigated as 
an anxiolytic at a 30 mg divided dosage, 
(Salkind et al 1979, Wallis et al 1979, de Fi-
gueiredo et al 1981). 
Data from these earlier studies indicated 
that clobazam has a good maintenance of 
anxiolytic effect and could therefore be ef-
fective in a smaller dose and perhaps as a 
single dose schedule. 14  Cl.OIIA/AM AND DIAZEPAM IN ANXIETY NEUROSIS 
In this study all three treatment groups 
showed considerable improvement. A 
marked reduction in scores- was also ob-
served during the post-treatment placebo 
period. 
Clobazam as 20 mg in a single or divid-
ed dose showed therapeutic effect compar-
able to diazepam 5 mg t.i.d. A trend for bet-
ter anxiolysis was seen with the single dose 
regimen. 
All three treatment groups showed en-
couraging results on the somatic cluster of 
anxiety. It might therefore be interesting to 
study clobazam also in the treatment of de-
pression, especially since somat zation is a 
common presentation in Indian patients 
suffering from both anxiety neurosis and 
depression. 
The single dose of clobazam 20 mg was 
free from detrimental effects on motor per-
formance and these patients performed bet-
ter than those on diazepam. With the 
20 mg divided dose, clobazam patients had 
significantly better motor performance 
than the diazepam series. Side-effects were 
generally low with all three treatment 
schedules, and could not be attributed to 
the drugs under study. The study suggests 
further investigation with the single dose of 
20 mg especially since it offers convenience 
of therapy with good anxiolysis and no han-
gover effect. 
Though in the doses studied, clobazam 
and diazepam have superiority in lack of se-
dative effect evidenced in psychomotor 
pcrformace, the single dose regimen of clo-
bazam and its maintained anxiolysis after 
stopping treatment arc of importance in as-
sisting the gradual withdrawal from drug 
treatment thereby reducing the risk of ben-
zodiazepine dependence in patient popula-
tions, as suggested by Marks (1978). 
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